(Q51522929)

English

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

scientific article published on 10 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

0 references

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

phase III clinical trial

0 references

0 references

4

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

author name string

F Saad

1

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

J E Brown

2

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

C Van Poznak

3

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

S M Stemmer

5

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

A T Stopeck

6

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

I J Diel

7

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

S Takahashi

8

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

N Shore

9

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

D H Henry

10

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

C H Barrios

11

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

T Facon

12

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

F Senecal

13

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

K Fizazi

14

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

L Zhou

15

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

A Daniels

16

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

P Carrière

17

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

R Dansey

18

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

publication date

10 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

23

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

5

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

1341-1347

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Osteonecrosis of the jaw and bisphosphonates

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

A systematic review of bisphosphonate osteonecrosis (BON) in cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Osteonecrosis of the jaw and bevacizumab therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Bisphosphonates: mode of action and pharmacology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Bisphosphonate osteonecrosis of the jaw--a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR435

21 January 2018

Identifiers

10.1093/ANNONC/MDR435

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21986094

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51522929&oldid=1233648822"